Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant’s latest offshoots have likely rendered them obsolete. www.reuters.com/business/healthcare-pharmaceuticals/who-strongly-advises-against-use-two-covid-treatments-2022-09-15/?
The two therapies – which are designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells – were some of the first medicines developed early in the pandemic.
The virus has since evolved, and mounting evidence from lab tests suggests the two therapies – sotrovimab as well as casirivimab-imdevimab – have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favour with the U.S. health regulator.
Lalita Panicker is consulting editor, views, Hindustan Times, New Delhi